Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers

Area of Science:

• Neuro-oncology
• Cancer Biology
• Translational Medicine

Background:

• Rare central nervous system (CNS) tumors present significant challenges due to poor prognosis and limited treatment options.
• Historically, studying these rare cancers has been hindered by small patient cohorts.
• Recent advances in molecular profiling are identifying key drivers, enabling the development of better research models.

Purpose of the Study:

• To review the advantages and disadvantages of various preclinical models for rare CNS tumors.
• To emphasize the utility of in vitro, ex vivo, and in vivo models for different research stages.
• To highlight recent progress in generating and screening models for specific rare CNS cancers.

Main Methods:

• Review of current literature on preclinical model generation for rare CNS tumors.
• Analysis of in vitro, ex vivo, and in vivo model systems.
• Focus on models for ependymomas, histone mutated high-grade gliomas, and atypical teratoid rhabdoid tumors.

Main Results:

• Preclinical models, including in vitro, ex vivo, and in vivo systems, are essential for understanding rare CNS cancers.
• These models facilitate target discovery, mechanistic studies, and therapeutic validation.
• Specific examples of model development for ependymomas, histone mutated high-grade gliomas, and atypical teratoid rhabdoid tumors are discussed.

Conclusions:

• The development and utilization of representative preclinical models are critical for advancing targeted therapies for rare CNS cancers.
• These models offer a path forward for diseases currently lacking effective conventional treatments.
• Continued innovation in preclinical modeling is key to improving outcomes for patients with rare CNS tumors.